PropertyValue
?:abstract
  • The coronavirus SARS-CoV-2 at the origin of COVID-19 shares more than 70% genetic similarity with SARS-CoV-1 that was at the origin of 2003 SARS. Infection-associated symptoms are very similar between SARS and COVID-19 diseases and are the same as community-acquired pneumonia symptoms. Antibiotics were empirically given to SARS patients in the early stages of the pathology whereas a different strategy has been decided in the management of COVID-19 pandemic with a worldwide shutdown. The cytokine storm, both identified in SARS and COVID-19 severe cases, is generated through inflammasome activation, which opens therapeutic perspectives to counteract the pathogenic inflammation. As corticoids have numerous side effects that limit their use, focusing on anti-inflammasome agents could represent a safer alternative for patients with severe COVID-19.
?:creator
?:doi
?:doi
  • 10.26355/eurrev_202007_22293
?:journal
  • European_review_for_medical_and_pharmacological_sciences
?:license
  • unk
?:pmid
?:pmid
  • 32744716
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.
?:type
?:year
  • 2020-07-01

Metadata

Anon_0  
expand all